Trial Profile
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Gemcitabine
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 17 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 17 May 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2017 Planned End Date changed from 1 Jul 2012 to 1 Dec 2018.